- Huadong Medicine reported a net income of 3.51 billion yuan for the fiscal year.
- The net income surpassed estimates, which were set at 3.35 billion yuan.
- The company’s revenue for the fiscal year came in at 41.91 billion yuan.
- Revenue fell short of the forecast, which was 42.97 billion yuan.
- Investment sentiment is largely positive, with 22 buy ratings.
- There is also 1 hold recommendation and 1 sell recommendation for Huadong Medicine.
A look at Huadong Medicine Co Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Huadong Medicine Co Ltd A demonstrates a positive long-term outlook. With solid scores in Dividend, Growth, Resilience, and Momentum, the company is positioned well for future success. The value score also indicates that the company is reasonably priced in the market. Huadong Medicine Co Ltd A‘s diverse operations in wholesaling, retailing, manufacturing of medicines, pharmaceuticals, and medical instruments, including antibiotics and biochemical products, provide a strong foundation for continued growth and profitability.
Investors looking for a promising investment opportunity may find Huadong Medicine Co Ltd A attractive given its favorable Smart Scores across key factors. The company’s strong dividend, growth potential, resilience, and positive momentum reflect a well-rounded business with the ability to navigate market challenges and capitalize on opportunities. As a player in the healthcare and pharmaceutical industry, Huadong Medicine Co Ltd A‘s strategic positioning and product portfolio bode well for its sustained success in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
